Your browser doesn't support javascript.
loading
HLA-B*14:02-Restricted Env-Specific CD8+ T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection.
Leitman, Ellen M; Willberg, Christian B; Tsai, Ming-Han; Chen, Huabiao; Buus, Søren; Chen, Fabian; Riddell, Lynn; Haas, David; Fellay, Jacques; Goedert, James J; Piechocka-Trocha, Alicja; Walker, Bruce D; Martin, Jeffrey; Deeks, Steven; Wolinsky, Steven M; Martinson, Jeremy; Martin, Maureen; Qi, Ying; Sáez-Cirión, Asier; Yang, Otto O; Matthews, Philippa C; Carrington, Mary; Goulder, Philip J R.
  • Leitman EM; Department of Paediatrics, University of Oxford, Oxford, United Kingdom ellen_leitman@hms.harvard.edu.
  • Willberg CB; Harvard Medical School, Boston, Massachusetts, USA.
  • Tsai MH; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Chen H; Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
  • Buus S; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA.
  • Chen F; Vaccine and Immunotherapy Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Riddell L; Laboratory of Experimental Immunology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Haas D; Department of Sexual Health, Royal Berkshire Hospital, Reading, United Kingdom.
  • Fellay J; Integrated Sexual Health Services, Northamptonshire Healthcare NHS Trust, Northampton, United Kingdom.
  • Goedert JJ; Departments of Medicine, Pharmacology, Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Piechocka-Trocha A; School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Walker BD; Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Martin J; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA.
  • Deeks S; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA.
  • Wolinsky SM; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.
  • Martinson J; Department of Medicine, University of California San Francisco Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
  • Martin M; Department of Medicine, University of California, San Francisco, California, USA.
  • Qi Y; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Sáez-Cirión A; Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Yang OO; Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Matthews PC; Cancer and Inflammation Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Carrington M; Cancer and Inflammation Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Goulder PJR; Institut Pasteur, Unité HIV, Inflammation et Persistance, Paris, France.
J Virol ; 91(22)2017 11 15.
Article en En | MEDLINE | ID: mdl-28878089
ABSTRACT
Immune control of human immunodeficiency virus type 1 (HIV) infection is typically associated with effective Gag-specific CD8+ T-cell responses. We here focus on HLA-B*14, which protects against HIV disease progression, but the immunodominant HLA-B*14-restricted anti-HIV response is Env specific (ERYLKDQQL, HLA-B*14-EL9). A subdominant HLA-B*14-restricted response targets Gag (DRYFKTLRA, HLA-B*14-DA9). Using HLA-B*14/peptide-saporin-conjugated tetramers, we show that HLA-B*14-EL9 is substantially more potent at inhibiting viral replication than HLA-B*14-DA9. HLA-B*14-EL9 also has significantly higher functional avidity (P < 0.0001) and drives stronger selection pressure on the virus than HLA-B*14-DA9. However, these differences were HLA-B*14 subtype specific, applying only to HLA-B*1402 and not to HLA-B*1401. Furthermore, the HLA-B*14-associated protection against HIV disease progression is significantly greater for HLA-B*1402 than for HLA-B*1401, consistent with the superior antiviral efficacy of the HLA-B*14-EL9 response. Thus, although Gag-specific CD8+ T-cell responses may usually have greater anti-HIV efficacy, factors independent of protein specificity, including functional avidity of individual responses, are also critically important to immune control of HIV.IMPORTANCE In HIV infection, although cytotoxic T lymphocytes (CTL) play a potentially critical role in eradication of viral reservoirs, the features that constitute an effective response remain poorly defined. We focus on HLA-B*14, unique among HLAs associated with control of HIV in that the dominant CTL response is Env specific, not Gag specific. We demonstrate that Env-specific HLA-B*14-restricted activity is substantially more efficacious than the subdominant HLA-B*14-restricted Gag response. Env immunodominance over Gag and strong Env-mediated selection pressure on HIV are observed only in subjects expressing HLA-B*1402, and not HLA-B*1401. This reflects the increased functional avidity of the Env response over Gag, substantially more marked for HLA-B*1402. Finally, we show that HLA-B*1402 is significantly more strongly associated with viremic control than HLA-B*1401. These findings indicate that, although Gag-specific CTL may usually have greater anti-HIV efficacy than Env responses, factors independent of protein specificity, including functional avidity, may carry greater weight in mediating effective control of HIV.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Péptidos / Infecciones por VIH / VIH-1 / Proteínas gp160 de Envoltorio del VIH / Productos del Gen gag del Virus de la Inmunodeficiencia Humana / Antígeno HLA-B14 / Inmunidad Celular Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Adult / Humans Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Péptidos / Infecciones por VIH / VIH-1 / Proteínas gp160 de Envoltorio del VIH / Productos del Gen gag del Virus de la Inmunodeficiencia Humana / Antígeno HLA-B14 / Inmunidad Celular Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Adult / Humans Idioma: En Año: 2017 Tipo del documento: Article